Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies | Zendy

C.E.M. Griffiths | Zendy; Maurizio Fava | Zendy; Andrew H. Miller | Zendy; James Russell | Zendy; Susan Ball | Zendy; Wen Xu | Zendy; Nayan Acharya | Zendy; Mark Hyman Rapaport | Zendy

Open Access

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

Author(s) -

C.E.M. Griffiths,

Maurizio Fava,

Andrew H. Miller,

James Russell,

Susan Ball,

Wen Xu,

Nayan Acharya,

Mark Hyman Rapaport

Publication year - 2017

Publication title -

psychotherapy and psychosomatics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.531

H-Index - 98

eISSN - 1423-0348

pISSN - 0033-3190

DOI - 10.1159/000479163

Subject(s) - ixekizumab , medicine , psoriasis , placebo , gastroenterology , systemic inflammation , population , psoriasis area and severity index , depression (economics) , inflammation , immunology , psoriatic arthritis , pathology , secukinumab , alternative medicine , environmental health , macroeconomics , economics

Depression is a common comorbidity in psoriasis, and both conditions are associated with systemic inflammation. The efficacy of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, was evaluated in patients with moderate-to-severe plaque psoriasis (psoriasis) and depressive symptoms that were at least moderately severe.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research